



US PATENT ISSUED PROTECTING BARD1 TECHNOLOGY FOR BREAST AND OVARIAN CANCER DIAGNOSIS

- US patent granted covering breast and ovarian cancer diagnosis
- Protects BARD1 autoantibody tests for detection of breast and ovarian cancer

Melbourne, Australia, 17 January 2022: INOVIQ Limited (ASX:IIQ) (**INOVIQ** or the **Company**) is pleased to announce that US Patent 11,193,944 titled 'Kits for detecting breast or ovarian cancer in a body fluid sample and use thereof' was issued by the United States Patent and Trademark Office (USPTO).

The issued US Patent 11,193,944 is a continuation of US 10,018,639 with additional claims directed towards a method for detecting BARD1 autoantibodies associated with breast or ovarian cancer in body fluids and related assays, kits and peptides. The patent application was filed by INOVIQ Ltd (previously BARD1 Life Sciences Limited) on 13 June 2018 and is due to expire on 28 November 2032.

CEO Dr Leearne Hinch said: "There is an important unmet medical need for non-invasive, accurate and reliable tests for earlier detection and monitoring of breast and ovarian cancers to improve women's health outcomes. This patent provides IP protection for potential BARD1 autoantibody tests for detection of breast and ovarian cancer in the USA."

This BARD1 patent family now has three granted patents enforcing protection in the key US and European markets.

Authorised by the Company Secretary, Tony Di Pietro.

- ENDS -

COMPANY CONTACTS

Dr Leearne Hinch
Chief Executive Officer
E lhinch@inoviq.com
M +61 400 414 416

Dr Geoff Cumming
Non-executive Chairman
E geoff.cumming@inoviq.com
M +61 417 203 021

Jane Lowe
IR Department
E jane.lowe@irdepartment.com.au
M +61 411 117 774

ABOUT INOVIQ LTD

INOVIQ Ltd (ASX:IIQ) (**INOVIQ**) is developing and commercialising an innovative portfolio of diagnostic and exosome-based products to improve the diagnosis and treatment of cancer and other diseases. The Company has commercialised the hTERT test used as an adjunct to urine cytology testing for bladder cancer and the EXO-NET pan-exosome capture tool for research purposes. Our cancer diagnostic pipeline includes blood tests in development for earlier detection and monitoring of ovarian, breast, prostate, and other cancers. For more information on INOVIQ, see www.inoviq.com.

FORWARD LOOKING STATEMENTS

This announcement contains certain 'forward-looking statements' within the meaning of the securities laws of applicable jurisdictions. Forward-looking statements can generally be identified by the use of forward-looking words such as 'may', 'should', 'expect', 'anticipate', 'estimate', 'scheduled' or 'continue' or the negative version of them or comparable terminology. Any forecasts or other forward-looking statements contained in this announcement are subject to known and unknown risks and uncertainties and may involve significant elements of subjective judgment and assumptions as to future events which may or may not be correct. There are usually differences between forecast and actual results because events and actual circumstances frequently do not occur as forecast and these differences may be material. The Company does not give any representation, assurance or guarantee that the occurrence of the events expressed or implied in any forward-looking statements in this announcement will actually occur and you are cautioned not to place undue reliance on forward-looking statements.